NYR Nyrada Inc.
Healthcare · Biotechnology
· website
$0.52
52wk 0.29 – 1.44
Overall
33.0
Value
45.5
Growth
0.0
Health
100.0
Quality
0.0
Momentum
4.2
Dividend
—
Price
About Nyrada Inc.
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Price analytics
Returns
| 1 day | 4.0% |
| 1 week | 0.0% |
| 1 month | -27.8% |
| 3 months | 23.8% |
| 6 months | -20.0% |
| 1 year | 65.1% |
| 3 years | 2,263.6% |
Risk
| Volatility (1y ann.) | 113.6% |
| Beta vs ASX 200 | 1.55 |
| Sharpe (1y) | 0.94 |
| VaR 95% (1-day) | -9.3% |
| Max drawdown (1y) | -71.0% |
| Off 1-year high | -62.3% |
Technicals
| RSI(14) | 32 |
| vs 50DMA | -23.2% |
| vs 200DMA | -20.0% |
| Trend | Golden cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
45.5
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
4.2
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
20
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$134.51M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.03
Dividend yield
—
Payout ratio
0.0%
Beta
0.94
EV / EBITDA
-17.83
Price / Book
13.33
ROE
-100.0%
Operating margin
-284.0%
Net margin
0.0%
Total cash
$8.38M
Total debt
$0
Current ratio
11.94
Debt / Equity
—
Free cash flow
$-2.26M
Avg volume
331,618
Latest annual results
(FY ending 30 Jun 2026)
- Revenue—
- Gross profit—
- Operating income-$8.75M
- Net income-$6.56M
- Diluted EPS—
- Free cash flow-$4.52M
- Net debt-$8.38M